Updates On Ensuing Board Meeting On 25Th May, 2018.
In furtherance to our letter dated 17thMay, 2018, we wish to inform you that Board of Directors may consider declaration/recommendation of Dividend at their meeting scheduled to be held on Friday, the 25thday of May, 2018, at its corporate office at 37, Ujagar Industrial Estate, W.T. Patil Marg, Deonar, Mumbai- 400 088, Maharashtra, India. Board Meeting On May 25Th 2018
We wish to inform you that the meeting of the Board of Directors of the Company will be held on Friday, 25th May 2018 at the Corporate Office of the Company at Mumbai at 4.00 P.M.: To consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended March 31, 2018; Any other matter with the permission of the Chair. Further, pursuant to the Securities and Exchange Board of India... Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Neeta Mehta Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mukund Mehta Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bhavin Mehta Compliance Certificate Under Regulation 40(9) Of The SEBI(Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended March 31, 2018
Please find enclosed herewith Compliance Certificate Under Regulation 40(9) Of The SEBI(Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended March 31, 2018 Shareholding for the Period Ended March 31, 2018
Kilitch Drugs India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2018. For more details, kindly Click here Shareholding for the Period Ended March 31, 2018
Kilitch Drugs India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2018. For more details, kindly Click here Compliance Certificate As Per Regulation 7(3) Of SEBI (Listing Obligation And Disclosure Requirement) Regulations, 2015 For The Period Ended March 31, 2018.
Please find enclose Compliance Certificate of the Company as per Regulation 7(3) of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 for the period ended March 31, 2018. Statement Of Investor Complaints For The Quarter Ended March 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Mukund MehtaDesignation :- Director